Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02) by Sarah Bertoli, Emilie Bérard, Pierre Peterlin, Romain Guieze, Yohan Desbrosses, Yosr Hicheri, Omar Benbrahim, Martin Carre, Corentin Orvain, Anne Banos, Marc Bernard, Emmanuel Gyan, Alain Saad, Safia Chebrek, Gabrielle Roth Guepin, Veronique Dorvaux, Laurence Sanhes, Maria Pilar Gallego-Hernanz, Carole Exbrayat, Laure Vincent, Chantal Himberlin, Célestine Simand, Norbert Vey, Cindy Fenoll, Ariane Mineur, Anne Huynh, Francois Vergez, Isabelle Luquet, Laetitia Largeaud, Eric Delabesse, Arnaud Pigneux, Christian Récher, French Innovative Leukemia Organization FILO

Get full text

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS by Amy E. DeZern, Sylvain Thepot, Stephane de Botton, Andrea Patriarca, Dries Deeren, Jose-Miguel Torregrossa-Diaz, Giovanni Marconi, Teresa Bernal, Juan Bergua Burgues, Blanca Xicoy, Anna Jonášová, Amer M. Zeidan, Sophie Dimicoli-Salazar, Célestine Simand, David Valcarcel, Maria Diez Campelo, Wanxing Chai-Ho, Lalit Saini, Alice Garnier, Klaus Geissler, Yishai Ofran, Zsolt Nagy, Pramila Krishnamurthy, Michael Lübbert, Grzegorz Basak, Hetty E. Carraway, David A. Sallman, Uma Borate, Valeria Santini, Victoria Campbell, Pierre Fenaux, Thorsten Braun, Francesco Lanza, Jan Maciej Zaucha, David A. Roth, Sofia Paul, Pourab Roy, Michael J. Kelly, Angela Volkert, Jaime Chisholm, Tanya Abdul Malak, Virginia M. Klimek, Thomas Cluzeau

Get full text